Skip to main content

Table 3 Age-related prevalence of the MetS in subjects with different gender

From: Prevalence of metabolic syndrome (MetS) in Chinese subjects gradually increased with impaired glucose homeostasis: a multicenter, clinical based, cross-sectional study

  Male Female
NGT IFG/IGT T2D P value for trends NGT IFG/IGT T2D P value for trends
N 1559 1172 3376   782 296 2072  
<30 18.1%(15/83) 35.7%(5/14) 63.9%(115/180)***# P<0.001 3.3%(3/91)## 30.0%(3/10)* 54.9%(39/71)*** P < 0.001
%95CI (9.6–26.5) (7.0–64.4) (56.8–71.0) (−0.4–7.0) (−4.6–64.6) (43.1-66.8)
OR Ref 2.519(0.738–8.591) 8.021(4.244–15.157) Ref 12.571(2.129–74.233) 35.750(10.324-123.791)
30-39 20.0%(42/210) 73.3%(63/86)*** 75.1%(410/546)*** P<0.001 3.8%(4/106)&&& 34.8%(8/23)***&& 61.2%(137/224)&&& P < 0.001
%95CI (14.6–25.5) (63.7–82.8) (71.5–78.7) (0.09–7.5) (13.7–55.8) (54.7-67.6)
OR Ref 10.957(6.103–19.669) 12.059(8.166–17.807) Ref 13.600(3.644–50.754) 40.155(14.271-112.986)
40-49 26.1%(130/499) 69.1%(237/343)*** 74.2%(783/1055)*** P<0.001 15.7%(69/441)&&& 52.0%(93/179)***&&& 67.8%(328/484)***###& P < 0.001
%95CI (22.2–29.9) (64.2–74.1) (71.6–76.9) (12.2–19.1) (44.6–59.4) (63.6-72.0)
OR Ref 6.346(4.683–8.601) 8.171(6.409–10.417) Ref 5.830(3.948–8.610) 11.336(8.232-15.609)
50-59 28.0%(210/750) 64.2%(457/712)*** 74.1%(754/1018)***### P<0.001 19.7%(28/142)& 55.0%(44/80)*** 79.9%(563/705)***###&& P < 0.001
%95CI (24.8–31.2) (60.7–67.8) (71.4–76.8)   (13.1-26.3) (43.9-66.1) (76.9-82.8)  
OR Ref 4.608(3.694-5.749) 7.344(5.940-9.081) Ref 4.976(2.720-9.104) 16.142(10.267-25.380)
≥60 41.2% (7/17) 41.2%(7/17) 73.0%(421/577)**## P<0.001 50.0%(1/2) 75.0%(3/4) 84.4%(496/588)&&& P = 0.364
%95CI (15.1–67.3) (15.1–67.3) (69.3–76.6) (−5.9–6.9) (−4.6–154.6) (81.4-87.3)
OR Ref 1.000(0.255-3.919) 3.855(1.442-10.305) Ref 3.000(0.084-107.447) 5.391(0.334-86.965)
  1. Compared with NGT *P<0.05, **P<0.01, ***P<0.001; Compared with IFG/IGT #P<0.05, ##P<0.01, ###P<0.001; Compared with male group &P<0.05, &&P<0.01, &&&P<0.001.